Results 191 to 200 of about 1,046,192 (353)

​Did a Non‐Medical Biosimilar Switching Policy Cause an Increase in Non‐Biologic/Biosimilar Health Care Resource Utilization or Cost in Patients With Inflammatory Arthritis?

Arthritis Care &Research, EarlyView.
Objective This study aimed to evaluate the impact of a series of policies that mandated switching patients with inflammatory arthritis (IA) from an originator biologic to a biosimilar in British Columbia, Canada, on health care resource use and cost.
HaoHung Dang, Sandra Blitz, Nick Bansback, Michael Law, Mark Harrison   +4 more
wiley   +1 more source

Four Decades of Progress: Evaluating Saudi Arabia's Research Publications in Pharmaceutical Sciences. [PDF]

Hosp Pharm
Rohra DK, Memon I.
europepmc   +1 more source

Nanotechnology Inclusion in Pharmaceutical Sciences Education in Portugal. [PDF]

Am J Pharm Educ, 2018
das Neves J.
europepmc   +1 more source

A Review of Osmotic Pump Applications as a Reliable Drug Delivery System in Pharmaceutical Sciences

Samar Mahari, Seydeh Halimeh Najafi, Salar Masoomzadeh, Shalen Kumar, Tooba Gholikhani   +4 more
openalex   +1 more source

Pakistan Journal of Pharmaceutical Sciences

, 2019

openalex   +1 more source

Improvements in Health‐Related Quality of Life With Treat‐to‐Target Urate‐Lowering Therapy in Gout: A Post Hoc Analysis of a Randomized Multicenter Trial

Arthritis Care &Research, EarlyView.
Objective Although treat‐to‐target urate‐lowering therapy (ULT) is endorsed as best practice in gout management, limited data exist on its impact on health‐related quality of life (HRQoL). We assessed the impact of treat‐to‐target ULT on HRQoL among participants receiving protocolized gout care, identifying factors associated with HRQoL and HRQoL ...
Austin Barry, Bryant R. England, Harlan Sayles, Lindsay N. Helget, Maria Androsenko, Hongsheng Wu, Kaleb Michaud, Bridget Kramer, Jeff A. Newcomb, Mary T. Brophy, Anne Davis‐Karim, Ryan Ferguson, Michael H. Pillinger, Tuhina Neogi, Paul M. Palevsky, James R. O'Dell, Ted R. Mikuls   +16 more
wiley   +1 more source

Pharmaceutical Sciences

Journal of African Studies, 1971
openaire   +2 more sources

Retraction notice to “Porphyrins to restrict progression of pancreatic cancer by stabilizing KRAS G-quadruplex: In silico, in vitro and in vivo validation of anticancer strategy” [European Journal of Pharmaceutical Sciences 125 (2018) Pages 39-53]

Rudradip Pattanayak, Atish Barua, Amlan Das, Tanima Chatterjee, Adrija Pathak, Pritha Choudhury, Srikanta Sen, Prosenjit Saha, Maitree Bhattacharyya   +8 more
openalex   +1 more source

High‐Pressure Biotechnology in Medicine and Pharmaceutical Science [PDF]

, 2001
Patrick Masson, Carole Tonello, Claude Balny   +2 more
openalex   +1 more source

Heterogeneity of Rheumatoid Arthritis–Associated Interstitial Lung Disease by Longitudinal Forced Vital Capacity Trajectory and Associations With Disease Outcomes

Arthritis Care &Research, EarlyView.
Objective We aimed to identify unique disease trajectories within rheumatoid arthritis–associated interstitial lung disease (RA‐ILD) based on longitudinal forced vital capacity (FVC) values and their associated clinical outcomes. Methods We performed a cohort study of RA‐ILD within the Veterans Health Administration from 1999 to 2021.
Bryant R. England, Yangyuna Yang, Punyasha Roul, Tate M. Johnson, Scott M. Matson, Grant W. Cannon, Brian C. Sauer, Jeffrey R. Curtis, Joshua F. Baker, Ted R. Mikuls   +9 more
wiley   +1 more source